Declines in Selling Prices Due to Changes in Healthcare Policy
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: FY2026-H1.
Mani moved to the "Worse" side of this theme in 2026, 8 years after the typical company in this theme (2018).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「As inventory adjustments at distributors in China continued under the impact of restrictions on the number of surgeries resulting from China’s healthcare spending policies, both net sales and segment profit posted modest growth.」
The disclosure expands the description of how healthcare policy risk may emerge beyond official price and selling price declines to include the impact of China's healthcare spending policies on the number of surgeries and distributor inventory adjustments. - FY2023RestatedAnnual report
「At our main plant in Vietnam, in addition to continuously reducing manufacturing costs by promoting process automation, we are working to minimise these effects by selling high-value-added products that capitalise on our fine-processing technology.」
The company describes measures to mitigate the risk of official price revisions and selling price declines resulting from healthcare policy through automation at the Vietnam plant and sales of high-value-added products. - FY2017First statedAnnual report
「Reviews of the official prices of medical fees, drug price standards and specified insurance medical materials, most of which result in reductions, are conducted approximately once every 2 years. As a result, selling prices may decline by more than anticipated, potentially affecting the Group's financial position and operating results.」
The company separately identifies the risk that reviews of official prices under healthcare cost-containment policies, conducted approximately once every 2 years, could lead to selling prices falling more than anticipated.